Prostate Cancer Prevention by Sulforaphane, a Novel Dietary Histone Deacetylase Inhibitor

Abstract

Prostate cancer is the second leading cause of cancer related death in men. To test Sulforaphane (SFN) as a novel histone deacetylases (HDAC) inhibitor and explore the mechanism of SFN protection against prostate cancer, different stage of prostate cancerous cells were treated with 15muM or 30 muM SFN and harvest 48hr later for MTT assay, HDAC activity and western blot assay. MTT cell proliferation showed that SFN and its metabolites inhibited PC3 prostate cancerous cell growth. SFN also inhibited HDAC activity in prostate cancerous cell alone but not normal cells. SFN selectively induced cell cycle arrest in prostate cancer cells, but not normal prostate cells. SFN treatment reduced the HDAC1 and HDAC3 protein level in PC3 cells and increased the acetylated histone H4. All the study showed that SFN is a HDAC inhibitor and protected against cancer development through epigenetic alteration in prostate cancer cells.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jan 01, 2008
Accession Number
ADA481867

Entities

People

  • Yu Zhen

Organizations

  • Oregon State University

Tags

DTIC Thesaurus Topics

  • Antineoplastic Agents
  • Apoptosis
  • Biomedical Research
  • Cancer
  • Cell Line
  • Cell Physiological Processes
  • Cells
  • Diseases And Disorders
  • Drug Therapy
  • Enzyme Inhibitors
  • Epithelial Cells
  • Inhibition
  • Inhibitors
  • Metabolites
  • Neoplasms
  • Prostate
  • Prostate Cancer

Fields of Study

  • Biology
  • Chemistry

Readers

  • Cellular and Molecular Pathways of Apoptosis.
  • Occupational Health and Safety.
  • Oncology (Cancer Research).